Recently, the Hurun Research Institute—one of the world’s most authoritative organizations for global entrepreneurship rankings—officially released the “2025 Hurun Future Unicorns: Global Gazelles Index.”

Hzymes Biotech Co., Ltd. (hereinafter referred to as “Hzymes”) has once again been recognized on the list, driven by its sustained innovation momentum, strong technological barriers, and high-speed growth potential. This distinction positions Hzymes as one of the world’s most promising high-growth enterprises with strong unicorn potential.

Award Ceremony (Hzymes Board Director & GM of Investment and Financing, Mr. Xilin Chen)

Authoritative Recognition from a Global Benchmark

Widely regarded as a global “barometer of growth,” the Hurun Global Gazelles Index applies extremely rigorous selection criteria. It focuses on companies founded after 2000 that are most likely to reach a USD 1 billion valuation within the next three years.

In 2025, only 819 Gazelle companies were selected worldwide. The United States ranked first with 302 companies, followed closely by China with 278.

Data from the report show that China’s Gazelle companies are primarily concentrated in biotechnology and semiconductor industries, which together account for 31% of the total—nearly one-third of all Chinese Gazelles—making them the core engines of growth. Among them, biotechnology stands out, with 119 companies on the list, highlighting the golden growth era of China’s biotech sector driven by rising healthcare demand and continuous technological breakthroughs.

Hard-Core Strength Behind the Honor

As a benchmark enterprise in China’s biotechnology sector, Hzymes successfully joined the ranks of the 119 biotech Gazelle companies, becoming a key representative of industry innovation.

Being listed again in 2025 is not only a recognition of Hzymes’ technological depth and market breakthroughs, but also a reflection of its precise alignment with key industry trends such as localization, import substitution, and technological self-reliance. By building strong upstream capabilities within the industrial chain, Hzymes continues to advance toward becoming a globally competitive biotech enterprise.

Hzymes’ core R&D team brings over 20 years of enzyme engineering experience. Leveraging six major technology platforms, including enzyme gene mining and AI-assisted design, the company has filed over 200 domestic and international patents and developed more than 3,500 products. Hzymes has successfully broken the long-standing technological monopolies of international giants in specialty enzymes, achieving import substitution for multiple key raw materials.

In terms of manufacturing capacity and quality control, Hzymes has invested nearly RMB 100 million to build a high-standard production system, including an 8,400 m² GMP facility and an enzyme–chemical catalysis base. With a 60,000-liter fermentation capacity, Hzymes has achieved industry-leading scale, delivering 2,000 kg of specialty enzymes annually and 10,000 kg of peptide raw materials per year, ensuring stable and high-quality supply for global customers.

Meanwhile, the company has established a comprehensive quality control platform and provides professional services such as one-stop recombinant protein CDMO and mRNA CRO services, empowering innovation across the biopharmaceutical value chain.

Conclusion

Being listed once again on the Hurun Global Gazelles Index is both an honor and a strong motivation. Beyond revenue growth, the Hurun evaluation emphasizes core technological barriers, business model innovation, industry influence, and global market potential, making it an important reference for global investors and industry institutions when identifying high-quality innovation-driven enterprises.

Looking ahead, Hzymes will continue to focus on breakthroughs in core biotechnologies, intensify investments in synthetic biology and AI-assisted enzyme design, and further strengthen its position within the global biotech value chain—contributing China’s innovation power to the advancement of the global biotechnology industry.